IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Confirmation No.: 6795

Andersen et al. Group Art Unit: 1654

Application Serial No.: 09/581,511 Examiner: Lukton, David

Filed: October 6, 2000 Attorney Docket No.: 108281-00000

For: Hemiasterlin Analogs

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450 Date: July 21, 2008

Sir

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Forms PTO-SB08a and SB08b. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

 \boxtimes This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date, OR (b) before the mailing date of a first Office Action on the merits in the present application, OR (c) accompanies a Request for Continued Examination. No certification or fee is required. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1). I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge

		designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
		c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
	or Not hereb Attach under overp	This Information Disclosure Statement is being filed more than three is after the U.S. filing date and after the mailing date of a Final Rejection tice of Allowance, but before payment of the Issue Fee. Applicant(s) y petition(s) that the Information Disclosure Statement be considered. ned is our check in the amount of \$180.00 in payment of the petition fee 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any ayment to Deposit Account No. 01-2300 as needed to ensure deration of the disclosed information.
		a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
		b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
₃	4. recent	Copies of the U.S. Patent references are not enclosed in view of the t changes in the U.S. Patent rules effective October 21, 2004.
		Respectfully submitted,
		ARENT FOX LLP Yelee Y. Kim Registration No. 60,088
		registration No. 00,000

Customer No. 004372

1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 857-6395

R.IB/sab